Business Wire

Cirium Enhances Industry-Leading On-Time Performance Advisory Board with Three Esteemed Aviation Leaders

4.12.2024 13:12:00 EET | Business Wire | Press release

Share

Cirium, the world’s most trusted source of aviation analytics, has appointed three prominent aviation experts to its Airline and Airport On-Time Performance Advisory Board. The move underscores Cirium’s commitment to maintaining its position as the global gold standard for airline and airport performance analytics.

As the first and only company to establish an On-Time Performance Advisory Board, Cirium ensures an unbiased, data-driven view of operational excellence. The latest appointments—Eamonn Brennan, Scott McCartney, and Alex de Gunten—bring over 75 years of combined experience, enhancing the board’s mission to uphold Cirium’s reputation as the industry benchmark.

Jeremy Bowen, Cirium CEO, said “Adding Eamonn, Scott, and Alex to our Advisory Board is a confirmation of our unwavering commitment to operational reliability and excellence. Their unique perspectives, spanning safety, operations, performance, journalism, and global airline strategy, will amplify our ability to provide independent, accurate data and insights. Together, we are shaping the future of aviation performance analytics for our partners worldwide.”

Meet the New Advisory Board Members

Eamonn Brennan

Eamonn Brennan joins the board with a distinguished record of leadership in aviation safety, performance, and airspace management. Currently serving as a Non-Executive Director at Ryanair, Brennan was the Director General of EUROCONTROL from 2018 to 2022, steering the organization through pivotal challenges such as the record-setting summer of 2019 and the COVID-19 pandemic. During his tenure, he ensured the resilience of the European Air Traffic Network, overseeing 11 million annual flights.

Previously, Brennan served as Chief Executive of the Irish Aviation Authority (2002–2017), achieving significant advancements in safety, cost efficiency, and airspace management. A pioneer in privatization efforts, he led the Airline Group’s successful bid for the UK’s first partial privatization of an Air Navigation Service Provider. Brennan has also held key leadership roles, including Chairman of CANSO Global and the COOPANS Alliance.

Scott McCartney

Scott McCartney, a renowned aviation journalist and business consultant, brings decades of expertise in analyzing and reporting on industry trends. For over 20 years, he penned The Middle Seat, The Wall Street Journal’s celebrated travel column, where he launched its highly regarded airline performance rankings.

McCartney was part of the Pulitzer Prize-winning team of journalists for its coverage of 9/11 and the author of four acclaimed books. His numerous accolades include the George Polk Award and SABEW’s “Best in Business” honors. Currently, he serves as an adjunct professor at Duke University and hosts Airlines Confidential, a globally recognized business podcast. He also leads Middle Seat LLC, a consultancy specializing in media training and aviation research.

Alex De Gunten

A seasoned aviation executive with a global perspective, Alex de Gunten joins the board with over 20 years of strategic leadership experience. As Business Development Officer at HEICO Aerospace, he has played a pivotal role in advancing aerospace innovation.

Previously, de Gunten served as Executive Director of the Latin American and Caribbean Air Transport Association (ALTA), fostering collaboration among regional airlines to address industry challenges. He also drove international expansion efforts as Vice President at LAN Chile and Canadian Airlines International. A multilingual leader fluent in English, Spanish, and French, de Gunten is a sought-after speaker and advisor to organizations such as ALTA and TravelX.

Strengthening Cirium’s Advisory Board

Chaired by Cirium CEO Jeremy Bowen, the board now comprises a powerhouse of aviation expertise, including former airline executive Willy Boulter, ACI World Director General Luis Felipe de Oliveira, and Atmosphere Research Group President Henry Harteveldt.

Board member, Mike Malik Cirium’s Chief Marketing Officer also serves as On-Time Committee Chairperson, and Lydia Webb, Cirium’s Marketing Director – Americas & Strategic Programs, is the Board Secretary.

This strengthened board equips Cirium to continue delivering unmatched insights and analytics to airlines, airports, and other stakeholders in the aviation industry.

About Cirium

Cirium® is the world’s most trusted source of aviation analytics. The company delivers powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities with the clarity and intelligence they need to optimize their operations, make informed decisions, and accelerate revenue growth.

Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium® on LinkedIn or visit cirium.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204844057/en/

Contacts

For Cirium media inquiries please contact media@cirium.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye